Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 106

Results For "Oral"

1108 News Found

Algorithm to calculate number of years one lives with good health
Healthcare | October 12, 2021

Algorithm to calculate number of years one lives with good health

In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks


Everest Organics develops API for molnupiravir
News | October 12, 2021

Everest Organics develops API for molnupiravir

The drug is being developed at lab scale for the first-line of treatment of Covid-19


Intas launches the world's first SB-100mg Itraconazole
Drug Approval | October 12, 2021

Intas launches the world's first SB-100mg Itraconazole

Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption


Merck and Ridgeback seek EUA from U.S. FDA for molnupiravir
News | October 11, 2021

Merck and Ridgeback seek EUA from U.S. FDA for molnupiravir

If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19


WHO new Essential Medicines Lists focus on diabetes and cancer
Public Health | September 30, 2021

WHO new Essential Medicines Lists focus on diabetes and cancer

The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all


Tavneos (avacopan) approved for ANCA associated vasculitis in Japan
Drug Approval | September 28, 2021

Tavneos (avacopan) approved for ANCA associated vasculitis in Japan

It is the first orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan


Lancet publishes NanoFlu vaccine Phase 3 trial results
News | September 24, 2021

Lancet publishes NanoFlu vaccine Phase 3 trial results

The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine


Lincoln Pharma plans to launch Cephalosporin product portfolio soon
Drug Approval | September 21, 2021

Lincoln Pharma plans to launch Cephalosporin product portfolio soon

Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from the fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others


Imfinzi plus chemotherapy tripled patient survival at 3 years
Biotech | September 20, 2021

Imfinzi plus chemotherapy tripled patient survival at 3 years

The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting


Novartis’ Kisqali data indicates longest median survival in advanced breast cancer
Drug Approval | September 20, 2021

Novartis’ Kisqali data indicates longest median survival in advanced breast cancer

With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting